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ABSTRACT 
Iontophoresis is one of the most widely studied active technique for enhancing 
transdermal delivery of drugs. However, its ability to enhance the delivery of highly lipophilic 
compounds is poor due to lack of any charge and poor water solubility of molecules. Propofol, a 
sedative and anesthetic drug was chosen as a one of the model lipophilic drug in this study. 
Initially, feasibility of delivery of propofol phosphate, a water soluble prodrug of propofol, via 
transdermal route using iontophoresis in combination with chemical permeation enhancers was 
investigated. Cathodal iontophoresis in combination with 0.1% sodium dodecyl sulphate 
synergistically enhanced the flux of propofol phosphate. The Pharmacokinetic studies were 
performed in rat model and the results suggest the plausibility of achieving therapeutically 
relevant levels of propofol when delivered via transdermal route. However, the 
pharmacodynamics studies revealed that propofol phosphate would be required at ~10X the dose 
of propofol likely due to hydrophilicity and poor distribution into the brain. Therefore, it is 
crucial to discover approaches that would enhance the transdermal delivery of propofol in its 
parent form. The objective of using iontophoresis is to eventually utilize the feasibility of the 
technology to develop a programmable transdermal drug delivery system. Thus, transdermal 
delivery of propofol was studied by complexing with sulfobutyl ether-β-cyclodextrin (Captisol® 
CAP), a β-cyclodextrin derivative carrying ionizable groups to render propofol amenable to 
iontophoresis. The passive permeation flux of propofol was enhanced by four fold due to 
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complexation with CAP. Application of iontophoresis (0.5 mA/cm2) to CAP-propofol solution 
enhanced the transport of propofol by an additional four fold. Pharmacokinetic studies showed a 
significant enhancement in the bioavailability of propofol when delivery in the form of complex 
by iontophoresis. Further, in vitro transport studies carried out using ibuprofen and testosterone 
demonstrated the potential of CAP as transport enhancer for lipophilic drugs. From the 
mechanistic studies, the enhancement in the transport of lipophilic drugs after complexation was 
found to be due to multiple mechanisms such as transport of intact complex, enhanced 
thermodynamic activity of drug at the interface and prolonged recovery of barrier disrupted due 
to iontophoresis.  
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CHAPTER 1 
INTRODUCTION 
The skin is the body’s largest organ, accounting for more than 10% of body mass. The 
skin consists of four layers; the stratum corneum (non-viable epidermis (SC)), the remaining 
layers of epidermis, dermis and subcutaneous tissues. The outer most layer of the epidermis is 
SC, which is also known as horny layer or keratin layer. Cross section of SC consisting of 15-25 
flattened stacked, hexagonal and cornified cells. Each cell is about 40 μm in diameter and 0.5 μm 
in thickness and composed of insoluble keratins and lipids, accounting for about 5% of the SC 
weight. The dead cells in the SC protect the deeper tissue, and thus for the majority of the 
chemicals tested, diffusion through SC is often the rate limiting step1, 2. The viable epidermis is 
typically around 200 μm in thickness and it contains living cells such as keratinocytes, 
melanocytes, langerhans cells and merkel cells. Its main functions include synthesis of melanin 
for skin pigmentation, sensory perception and immune response.  
Dermis is five to seven times thicker than the epidermis (1 – 1.5 mm) and lies below the 
epidermis. It is a tough layer of horizontally arranged collagen and elastic fibers with 
fibroblasts3. the dermis has numerous structures embedded within it; blood and lymphatic 
vessels, nerve endings, pilosebaceous units (hair follicles and sebaceous glands) and sweat 
glands (eccrine and epocrine). This layer offers a minimal barrier to the delivery of polar to 
moderately lipophilic drugs.  
Transdermal delivery of therapeutic agents provide several advantages which includes 
avoidance of first pass metabolism, easy termination of dose by removal of patch, easy 
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application for extended period of time by controlling the drug release and many more. The skin 
is poorly permeable to drugs, which are hydrophilic (log P < 1). Thus, to enhance the delivery of 
hydrophilic drugs, chemical permeation enhancers (CPEs) are being utilized in 
dermal/transdermal products. CPEs are chemical substances which facilitate transport of co-
administered substances across the skin, mainly by reversibly disrupting the highly ordered 
structure of stratum corneum lipids4. 
  It is well known that the drugs with log P 1-3 (moderately lipophilic) and molecular 
weight of < 500 Da are well permeable across the skin5. The rate of permeation of moderately 
lipophilic drugs is mainly controlled by the permeability of the skin. Not many approaches are 
known to enhance the rate of delivery of moderate lipophilic drugs till date, when there is 
requirement of a higher dose or a higher input rate due to rapid clearance of the drug from the 
body. Likewise, the extremely lipophilic drugs (log P≥3) would generally penetrate the lipid 
domains in the stratum corneum; yet fail the transit further due to highly hydrophilic 
environment of the viable epidermis and dermal tissues. The use of chemical enhancers (that are 
used to enhance the delivery of hydrophilic drugs) most of which perturb the lipid organization 
would rather hamper the delivery of lipophilic drugs. Therefore, the main objective of the present 
work was to explore the approaches to enhance the delivery of lipophilic drugs.  
Iontophoresis is one of the widely studied active techniques that involve passing 
electrical current across the skin in the presence of conductive vehicle. As a result, ions migrate 
through the skin towards the electrode of opposite charge. The amount of drug delivered is 
directly proportional to amount of current applied, duration of current application and area of the 
skin surface in contact with active electrode. Unlike all other techniques, iontophoretic delivery 
being programmable, the rate of delivery of drugs could be regulated by adjusting the applied 
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electrical dose (time x current density)6. However, iontophoresis is not suitable for nonpolar 
drugs as they lack any charge and possess poor water solubility.  The second main objective of 
this project was to investigate the potential approaches to render the lipophilic drugs amenable to 
iontophoretic delivery across the skin.  
Three test lipophilic therapeutic molecules were selected for the research that includes propofol 
(log P 4.12), ibuprofen (log P 3.5) and testosterone (log P 2.99). 
Transdermal Delivery of Propofol  
Propofol (2, 6-diisopropylphenol) is a centrally acting anesthetic usually administered 
through intravenous route. Induction of anesthesia with propofol is rapid, and maintenance of 
anesthesia can be achieved by either continuous infusion or intermittent bolus injections7. Due to 
its clinical safety and efficacy, use of propofol has become drug of choice for procedural 
sedation and is used alone or in combination with regional anesthetic agents, especially in case of 
pediatric population8-9. The American College of Emergency Physicians (ACEP) defines 
procedural sedation as "a technique of administering sedatives or dissociative agents with or 
without analgesics to induce a state that allows the patient to tolerate unpleasant procedures 
while maintaining cardiorespiratory function”.   
Propofol is a clear to slightly yellow oily liquid at room temperature and is highly 
lipophilic with a log P of 4.1510. Due to its poor water solubility, propofol is available as an 
injectable emulsion containing 1 or 2% of propofol11; hence has been reported to cause moderate 
to severe pain at the site of injection12-14. Since propofol emulsion is generally prepared with 
lipidic substances such as soybean oil and egg yolk lecithin, the patient suffers from side effects 
associated with high lipid intake15. The same is also responsible for other side effects that include 
serious allergic reactions, bradycardia, apnea and hypotension16, 17. Since propofol is viscous and 
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water immiscible, pulmonary delivery is not possible18. Oral route is not preferred for propofol 
administration either, as the hepatic extraction ratio of propofol was reported to be ~80-90%19. 
Therefore, there is need for development of alternate modes of administration of propofol. In this 
project, the skin as a route of administration of propofol was investigated. The first approach 
involved conversion of propofol to a relatively lesser lipophilic salt form propofol phosphate and 
the second approach was to complex with a poly-anionic cyclodextrin. Iontophoresis technology 
was used to achieve higher rates transdermal delivery of propofol.   
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CHAPTER 2 
TRANSDERMAL IONTOPHORETIC DELIVERY OF PROPOFOL IN THE FORM OF 
PHOSPHATE SALT 
1. Objective 
Iontophoresis is a non-invasive active technique that involves driving of drug ions by the 
way of application of mild electric current20. Delivery of propofol by iontophoresis would not be 
possible due to its water insolubility and non-polar nature. Therefore, a di-basic phosphate 
monoester (prodrug) form of propofol was synthesized and used in this project in order to 
improve its water solubility as well as to impart a charge on the molecule. Moreover, phosphate 
monoester is one of the most acceptable forms of active pharmaceutical ingredients, as it does 
not potentiate toxicity of the parent drug21.  
2. Materials 
Propofol, butyllithium (2.5 M in hexanes), propylene glycol, sodium dodecyl sulphate, 
di-methyl sulfoxide and phosphorus oxychloride were purchased from Sigma Aldrich (St. Louis, 
MO), anhydrous ether was purchased from Fisher Scientific (Pittsburgh, PA), Ag/AgCl wire was 
purchased from Alfa Aesar (Ward Hill, MA) and hydroxylpropyl methylcellulose (grade E4M) 
gift sample was provided by The Dow Chemical Corporation (Midland, MI). All reagents used 
were of analytical grade and highly purified deionized water (resistivity ≥ 18.2 MΩ.cm, Barnsted 
Nanopure DiamondTM, Barrington, IL) was used for the preparation of all solutions. 
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3. Methods 
3.1. Synthesis of Propofol Phosphate (PP)  
PP was synthesized by following two steps.  In step 1, 2.24 mL of 2.5 M solution in 
hexanes of butyllithium (5.6 mM) was added drop wise to 1.0 g of propofol (5.6 mM) in 10 mL 
of anhydrous ether under inert atmosphere at -30 ˚C. The solution was stirred for 30min and then 
allowed to warm to room temperature. In step 2, the solution from step 1 was added drop wise to 
a solution of 0.918 g of phosphorus oxychloride (6.0mM) in 10 mL of ether at -30 ˚C under inert 
atmosphere. The solution was allowed to stir until the mixture comes to room temperature. Then 
5mL of water was added to the reaction mixture and allowed it to stir for 1 h. 35 mL of sodium 
hydroxide (1M) and 30 mL of n-hexane was then added and the aqueous phase was washed with 
n-hexane to remove unreacted propofol. Aqueous phase was evaporated to dryness and the solid 
residue obtained was extracted with ethyl acetate to get propofol phosphate (Yield was found to 
be ~69%). 
3.2. NMR and Mass Spectrum Studies 
Chemical structure of the PP salt was characterized by high resolution nuclear magnetic 
resonance spectra (1H NMR and 13C NMR). Spectra’s were recorded on a Brucker Ultraspec 400 
MHz/100 MHz spectrometer. Chemical shifts were reported in parts per million (δ) and 1H NMR 
signals were quoted as s (singlet), d (doublet), t (triplet) and m (multiplet). Electro spray 
ionization mass spectrum was recorded on waters micromass (ZQ MM1-LAA 1780).  
3.3. In vitro studies 
3.3.1. Passive permeation setup 
In vitro skin permeation studies were performed using Franz diffusion apparatus (FDA) 
and freshly excised hairless rat abdominal skin. The skin was sandwiched between the donor and 
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receiver compartment with the stratum corneum facing the donor side. The temperature was 
maintained at 37 ± 1◦C by using a water circulator. The donor compartment was filled with 0.5 
mL of drug solution/ formulation and the receiver compartment with 5 mL of saline. The active 
diffusion area was 0.64 cm2. The electrodes were made out of Ag/AgCl. The electrical resistance 
of the rat skin was measured using digital multi meter and waveform generator (Agilent 
Technologies, Santa Clara, California). Skin with resistance 20 kΩcm2 and greater was used for 
the permeation study. The samples from the receiver compartment were collected at 
predetermined time points to estimate the amount of propofol/PP permeated across the skin, 
using high-performance liquid chromatographic technique (HPLC). All the points in the graphs 
representing in vitro studies are average of six trials ± SD. 
3.3.2. Concentration dependent in vitro permeation of PP 
In vitro permeation studies were carried out with four different concentrations of PP (1, 5, 
30 and 100 mg/mL) in the donor to investigate the effect of concentration on the passive 
transdermal flux. 
3.3.3. Effect of Chemical Permeation Enhancer on the permeation of PP  
The effect of chemical permeation enhancers (CPE) like propylene glycol (PG), sodium 
dodecyl sulphate (SDS) and dimethyl sulfoxide (DMSO) at 30%, 0.1% and 30% concentration 
levels respectively, on the passive transdermal flux of PP was assessed. The enhancer, with 
relatively higher enhancement efficiency was chosen for further studies. 
3.3.4. Iontophoretic delivery of PP 
A similar Franz diffusion cell setup described in the previous section was used in this 
study. Constant current cathodal iontophoresis was performed using Phoresor iontophoresis unit 
(Iomed, Salt Lake City, Utah) at a current density of 0.5 mA/cm2. The donor compartment was 
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filled with 30 mg/mL of PP and the receiver compartment with 5 mL of saline. One milliliter of 
samples was collected from the receiver compartment at predetermined time points and analyzed 
for PP using HPLC. 
3.3.5. Effect of combination of chemical permeation enhancer with iontophoresis 
The effect of sodium dodecyl sulfate (SDS) on iontophoretic flux was evaluated by 
incorporating SDS in the donor compartment along with PP, at concentration level of 0.1% W/V. 
3.3.6. Iontophoretic delivery of PP from gel formulation  
 Semi-solid gel formulation was prepared using hydroxypropyl methylcellulose (HPMC) 
using hot/cold technique22. Briefly, one-third of the total volume of water was heated to 90◦C and 
the HPMC (4% w/ v) was incorporated with continuous stirring until a uniform dispersion was 
obtained. PP was dissolved in remaining amount of water and then added to the HPMC 
dispersion, under continuous stirring. The solution was cooled to 30◦C to form a semi-solid gel 
while continuously stirring for homogeneity. In vitro drug transport studies were performed, by 
placing 1 g of gel formulation in the donor compartment. The other experimental conditions 
were maintained same as discussed under the section Iontophoretic Delivery of PP 
3.4. Pharmacokinetic studies 
 Pharmacokinetic studies were carried out in Sprague–Dawley rats. The Institutional 
Animal Care and Use Committee (IACUC) at the University of Mississippi (IACUC #11-008) 
approved the studies. The rats were divided into two groups (n = 6) with one group serving as 
control (passive) and the other as iontophoresis group. The animals were anesthetized using 
ketamine (80 mg/mg) and xylazine (10 mg/kg) via intraperitoneal route during the period of 
study. 
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 Custom-designed reservoir type patch of 10cm2 area were used for pharmacokinetic 
studies. The patch was designed by loading 2 g of HPMC gel formulation containing 30 mg/mL 
PP and 0.1% SDS, on the polyolefin backing membrane. The patches were placed on the dorsal 
skin surface of the rat. Alongside, another patch containing conducting gel (Sigma gel; Parker 
Laboratories, Inc., Fairfield, New Jersey) was also placed 2 cm apart on the dorsal surface of the 
rat. To perform iontophoresis, cathodal electrode was connected to the patch containing propofol 
gel formulation, and the anodal electrode was connected to the patch containing conducting gel. 
Iontophoresis was performed by applying constant current of 0.5 mA/cm2 across the electrodes 
by using Iomed Phoresor II dose controller (Iomed Inc.) for a period of 4 h. In case of control, 
the set up was similar except that the current was not applied. Blood samples were collected into 
dry heparinized tubes from the retro orbital plexus for 6 h, at predetermined time points. 
Propofol was then extracted and estimated from the blood samples using a validated HPLC 
method as described under section Analytical Methods. 
3.5. Method for Extraction of Propofol from Plasma  
 Samples Plasma was separated from the blood samples by centrifugation. One milliliter 
of acetonitrile was added to 100 μL of plasma and vortexed. The mixture was centrifuged at 
15,000g for 10 min at 4◦C. The clear supernatant was then separated and the propofol content 
was measured using HPLC 
3.6. Analytical Methods 
The HPLC system (Waters Corp, Milford, MA) consisting of model 1525 isocratic 
chromatographic pump equipped with an autosampler (Waters 717 plus), a UV detector (Waters 
2487) and a reversed phase symmetry® C18 (4.6 x 150 mm; 5 µm particles) column with a 
security guard cartridge, was used. Analyses of PP samples were carried out at a wavelength of 
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214 nm, and the mobile phase consisted of a mixture of water, acetonitrile and tri-fluroacetic 
acid (55:45:1 v/v) with an optimized flow rate of 1mL/min.  
Propofol extracted from plasma samples was analyzed at 270 nm with mobile phase 
consisting of water and methanol (20:80 v/v)23. Calibration curves were prepared using methanol 
as solvent and the linearity was (R2 > 0.99) over the concentration range 10 to 10,000 ng. 
4. Results and Discussion 
Propofol phosphate di-sodium salt (a white crystalline solid) was synthesized and its 
structure was characterized by 1H NMR and 13C NMR. Electron spray ionization mass spectrum 
study confirmed the mass of PP (303.2 Da). Chemical structure of propofol and propofol 
phosphate was shown in figure 1. Results obtained from the NMR and mass spectrum were 
consistent with the structure. 1H NMR and 13C NMR chemical shift values of propofol and 
propofol phosphate was given in the Table 1 and Table 2, respectively. 
 
 
 
Figure 1: Structure of Propofol and Propofol Phosphate 
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S.No Protons Chemical Shift 
Propofol (CDCl3) PP (D2O) 
1 Isopropyl CH3’s 1.43(d) 1.10(d) 
2 Isopropyl CH’s 3.31(m) 3.44(m) 
3 -OH 4.96(s) - 
4 Ar-C4-H 7.07(t)  
7.14(m) 5 Ar-C3-H & C5-H 7.23(d) 
 
Table 1: 1H NMR chemical shifts of propofol and propofol phosphate. Singlet (s), Doublet 
(d), Triplet (t) and Multiplet (m) 
 
S.No Carbons Chemical Shift 
Propofol (CDCl3) PP (D2O) 
1 Isopropyl terminal ‘C’ s 22.7 22.7 
2 Isopropyl middle ‘C’ s 27.1 26.6 
3 Ar-C3 & C5 120.6 123.9 & 123.9 
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4 Ar-C4 133.6 125.0 
5 Ar-C2 & C6 123.4 141.6 & 141.7 
6 Ar-C1 149.9 147.0 
 
Table 2: 13C NMR chemical shifts of propofol and propofol phosphate 
 
4.1. Spectral Data  
Propofol: 1H NMR (400 MHz, Chloroform-d) δ 7.23 (d, J = 7.6 Hz, 2H), 7.07 (t, J = 7.6 Hz, 
1H), 4.96 (s, OH), 3.31 (h, J = 6.9 Hz, 2H), 1.43 (d, J = 6.9 Hz, 12H). 13C NMR (101 MHz, 
cdcl3) δ 149.87, 133.62, 123.36, 120.61, 27.07, 22.70. ESI-MS: 179 (M+1).  
Propofol Phosphate: 1H NMR (400 MHz, D2O) δ 7.17–7.07 (m, 3H), 3.44 (p, J = 6.9 Hz, 2H), 
1.10 (d, J = 6.9 Hz, 12H). 
13C NMR (101 MHz, D2O) δ 147.00, 141.66, 141.63, 125.01, 123.96, 123.94, 26.57, 22.72. 
ESI-MS: 303 (M+1). 
4.2. Concentration dependent in vitro permeation of PP 
In vitro passive permeation studies were performed at four different concentrations (1, 5, 
30 and 100 mg/mL) to assess the effect of concentration on the steady state transdermal flux of 
PP. From the results it was found that, an increase in PP concentration from 1-30 mg/mL 
increased the steady state flux from 1.90±0.21 µg/cm2/h to 8.52±0.82 µg/cm2/h respectively. 
However, further increase in concentration to 100 mg/mL, did not lead to significant 
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proportionate increase in the flux (9.83±1.12 µg/cm2/h) (Fig 2). Therefore, further studies were 
performed at donor concentration of 30 mg/mL of PP.  
 
Figure 2: The effect of concentration of propofol phosphate  in the donor on its 
transdermal flux 
4.3. Effect of chemical permeation enhancers on the passive permeation of PP 
 Chemical permeation enhancers are known to enhance the permeation of therapeutic 
agents across the skin. Predominantly, the mechanism of enhancement has been due to the 
interaction with the stratum corneum (skin lipids or proteins or both) and/or owing to the 
increase in the thermodynamic activity of drugs24. In this study, some of the well-known skin 
permeability enhancers such as PG, SDS, and DMSO were used as CPEs at 30% v/v, 0.1% w/v, 
and 30% v/v concentration levels, respectively. PG is known to increase the solubility of drugs in 
the skin lipids and thereby enhance the permeability of therapeutic agents. Yamato et al25 studied 
the effect of different CPEs on transdermal permeation of propofol. The authors reported a 
fourfold enhancement in the in vitro permeation flux of propofol across the rat abdominal skin 
when 30% PG was used as CPE. However, in the present study PG (at the same concentration) 
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decreased the in vitro passive permeation flux of PP [6.23 ± 1.03 μg/cm2/h with PG vs. 8.52 ± 
0.82 μg/cm2/h in case of control].  
Dimethyl sulfoxide was the other enhancer screened in the present study, as it is one of 
the widely used transdermal permeation enhancer. Several studies have demonstrated that 
DMSO is effective in promoting the permeation of larger number of hydrophilic and lipophilic 
molecules.26,27 The enhancer effect is reported to be concentration dependent and at 
concentration above 60%, it has been reported to extract skin lipids apart from altering the 
protein structure and thereby enhances the permeation of drug molecules.24 However, at this high 
concentration, DMSO has been shown to cause erythema and burning sensation.28 Zafar et al.29 
have studied the effect of various penetration enhancers along with DMSO to deliver labetalol 
hydrochloride via transdermal route. From the in vitro permeation studies, they concluded that, 
upon increasing the concentration of DMSO, the enhancement factor was found to increase and 
showed maximum enhancement (1.165) at 10% v/v.29 Therefore, in the present study, DMSO 
was studied as permeation enhancer at 30% concentration. However, the passive transdermal 
flux of PP was not enhanced even in presence of DMSO [8.12 ± 2.08 μg/cm2/h]. 
Treating epidermis with surfactants has been demonstrated to significantly decrease the 
skin barrier functionality, in percutaneous drug absorption.30 SDS, an anionic surfactant, known 
to interact with the skin proteins and lipids thereby enhances the percutaneous absorption.31,32 
Surfactants are known to cause skin irritation upon exposure to higher concentrations.33,34 In the 
present study, effect of SDS was investigated at 0.1% concentration level, at which it is known to 
be safe to use.35 In a skin irritation study performed by Agner and Serup35 on human subjects, the 
dose–response relationship on skin irritation was studied and the response was quantified by 
measuring transepidermal water loss, blood flow, skin color, and edema in the skin. From the 
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irritation studies, authors concluded that the irritation potential increased significantly rapidly 
only after 0.25%. The results clearly indicate the clinical safety of SDS use at 0.1% 
concentration levels. Wang et al.36 have studied the effect of SDS on permeation of 
hydrocortisone; they found that the hydrocortisone flux was increased by approximately fourfold 
at 0.1% SDS when compared with control.36 In agreement with these results, the passive 
permeation flux of PP in the presence of 0.1% SDS resulted in the flux of 13.43 ± 0.73 μg/cm2/h, 
which was significantly higher than passive flux in case of control. Therefore, further studies 
were carried with SDS as permeation enhancer at 0.1% concentration level.  
       Several clinical investigation reports on propofol pharmacokinetics have been published 
till date. In general, the target propofol plasma concentration for sedation at level 2 (drowsy), 3 
(drowsy, responds to verbal stimulations) and 4 (responsive to physical stimulation only) were 
found to be 1-2 µg/ml37. Daisuke and co-workers have assessed the required plasma 
concentration of propofol and infusion rate of achieving sedation level 3 in humans. The authors 
reported that the target plasma concentration of propofol required for achieving sedation score of 
level 3 is 0.85 ± 0.24 µg/mL. With the clearance value of propofol being 1.83 L/min, the 
required input rate for achieving the above mentioned plasma concentration was 1.74 mg/kg/h38. 
Based on these reports, the required target rate of input of propofol phosphate (1.7M 
concentration of propofol phosphate is equal to 1M of propofol) would be 2.98 mg/kg/h. For the 
purpose of this project, if one considers pediatric patient of weight ~2 kg, then the average 
transdermal input rate (from the overall patch) to be achieved would be 5.96 mg/h. If the 
proposed size of the delivery device is about 10 cm2, then the target flux to be achieved would be 
596 µg/h/cm2.   
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4.4. Iontophoretic delivery of PP 
The iontophoresis application enhanced the transdermal flux of PP over passive (without 
SDS) by ~seven fold. However, there is need to improve the flux further to achieve the target 
flux. A number of studies have demonstrated the ability of chemical permeation enhancers to 
potentiate the effect of iontophoresis and improve the drug delivery significantly39-41. Rastogi 
and co-workers have studied the effect of CPEs on iontophoretic delivery of insulin. Results 
from their studies concluded that CPEs in combination with iontophoresis have enhanced the 
delivery of insulin by ~45 fold when compared to CPEs and iontophoresis alone42. In the present 
work, SDS was found to be one of the promising enhancer from passive drug permeation studies. 
Therefore, SDS was incorporated in the donor compartment solution with an objective of 
assessing the ability of SDS to enhance the iontophoretic mediated transdermal delivery of PP. 
The flux resulted from the in vitro iontophoretic transport studies in the presence of 0.1% SDS 
was found to be 306.2±32.82 µg/cm2/h, which was significantly (~fivefold) more when 
compared to iontophoresis of PP in the absence of SDS (60.37±8.63 µg/cm2/h) (Fig 3). More 
importantly, the iontophoretic flux of drug in presence of SDS was found to be somewhat nearer 
to calculated transdermal target flux. 
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Figure 3: Iontophoretic mediated delivery of PP across the rat skin, in presence of 
0.1% SDS in the donor (■) and without  SDS (♦) in the donor 
4.5. In vitro permeation of PP from gel formulation  
Hydroxypropyl Methylcellulose (HPMC) is widely used as suspending and stabilizing 
agent in various topical formulations, due to its semisynthetic and viscoelastic nature. High water 
content in HPMC gel formulation helps in good wetting, high partitioning of drug into the skin 
and also acts as a solvent medium for iontophoresis43. HPMC (4% W/V) gel prepared with 0.1% 
SDS and 30% PP was used for in vivo iontophoretic studies. Prior to in vivo studies, the 
iontophoresis mediated drug transport profile from the gel formulation was assessed across the 
rat skin. The steady state iontophoretic flux of PP from the gel was 249.24±6.12 µg/cm2/h, which 
was significantly less than that observed from the solution (306.2±32.82 µg/cm2/h) owing to the 
retarded ionic mobility due to higher viscosity of the gel (fig 4). At this flux, one would need 
approximately 2.4 times (23.9 cm2) the proposed area of application for the drug delivery device 
to achieve the target rate of input. Apparently, several transdermal drug delivery patches are of 
about this size and seems doing well from the patient acceptance standpoint. For example, 
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Estraderm MX® 100 is a marketed patch used to deliver estradiol with patch size of 44 cm2. 
Nitro-Dur®, is another example of marketed transdermal patch, which is used to deliver 
nitroglycerin with patch size of 40 cm2 and others include, Nicorette® is marketed to deliver 
nicotine with patch size of 30 cm2. Therefore, in the present study the required patch size (~24 
cm2) to achieve the target flux should be ideal and acceptable. 
 
Figure 4: In vitro permeation of PP from gel  formulation (♦) and solution (■) 
4.6. Pharmacokinetic Studies 
The Pharmacokinetic studies were performed in rat model to assess the feasibility of 
transdermal delivery of PP, in vivo. Following the transdermal delivery, PP is known to convert 
to propofol and inorganic phosphate, immediately upon entry into systemic circulation.  The time 
course of propofol concentration in plasma is shown in Fig 5. The amount of propofol present in 
plasma samples in control group (Passive) was below the detectable levels at all the time points 
during the study. Whereas, in case of iontophoresis group; initially, the plasma propofol 
concentration increased with time. However, there was no significant difference in the 
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concentration between 3rd and 4th hour indicating an inclination towards steady state 
concentration. Apparently, the drug has not formed a significant reservoir, as the plasma 
propofol concentration dropped significantly, immediately after the removal of the patch after 
fourth hour.  
 
Figure 5: Plasma concentration of propofol after transdermal delivery of PP at 30 mg/mL 
and 0.1% SDS with iontophoresis (♦) and without iontophoresis (■). 
The plasma concentration-time profile was fit to a non-compartmental model and the 
pharmacokinetic parameters were calculated. The elimination half-life of the drug was found to 
be 37.20 ± 6.82 min, which is in agreement with elimination half-life 24±12 min reported in the 
literature2. The results of this study demonstrate iontophoresis ability to deliver propofol via 
transdermal route.  
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5. Conclusions 
Combination of iontophoresis and chemical permeation enhancer, SDS was found to 
enhance the transdermal delivery of PP synergistically. These studies suggest that propofol could 
be delivered transdermally via iontophoresis in the form of its phosphate salt.  
However, the pharmacodynamics studies (unpublished data) revealed that propofol phosphate 
would be required at ~10X the dose of propofol likely due to hydrophilicity and poor distribution 
into the brain. Therefore, it is crucial to discover approaches that would enhance the transdermal 
delivery of propofol in its parent form. The objective of using iontophoresis is to eventually 
utilize the feasibility of the technology to develop a programmable transdermal drug delivery 
system.  
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CHAPTER 3 
TRANSDERMAL IONTOPHORETIC DELIVERY OF PROPOFOL BY COMPLEXING 
WITH ANIONIC CYCLODEXTRIN 
Graphical Abstract 
 
 
 Sulfobutyl ether-β-cyclodextrin  Propofol P-CAP Complex 
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1. Introduction  
Cyclodextrins (CDs) are commonly used as pharmaceutical excipients, mainly to solubilize 
the water insoluble drugs. CDs are cyclic oligosaccharides with a hydrophobic central cavity and 
hydrophilic outer surface. Their molecular structure attributes them some unique properties. The 
hydrophilic exterior of the CD makes them water soluble, but the hydrophobic cavity provides a 
microenvironment of appropriate size lipophilic molecules. In aqueous solutions, CDs are 
capable of forming inclusion complexes with many therapeutic agents by taking up a whole 
molecule or rather some non-polar part of the molecule into the hydrophobic cavity. The non-
covalent complex offers several advantages including the possibility of enhanced water solubility 
and solution stability44, 45.  
The objective of this project was to investigate, if cyclodextrin derivatives carrying ionizable 
groups could be utilized to complex with non-polar lipophilic drug, propofol to render it 
amenable to transdermal delivery by iontophoresis. Sulphobutyl ether-β-cyclodextrin (Captisol® 
(CAP)), a derivative of β-cyclodextrin with an average molecular weight of 2164 Da and seven 
negative charges due to ionizable sulfate group on its surface was chosen as complexing agent.  
2. Materials 
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand 
Pharmaceuticals, La Jolla, CA) and Rhodamine labeled CAP (R-CAP) was obtained from 
CycloLab Ltd, Budapest, Hungary. Propofol, deuterium oxide, deuterated chloroform, menthol, 
ethanol, oleic acid and propylene glycol was purchased from Sigma Aldrich Corporation, St 
Louis, MO. Ag wire was from Alfa Aesar, Ward Hill, MA. Isopropyl myristate and Dialysis 
membrane molecular weight cut off (MWCO) 1000Da was from Spectrum Chemicals, New 
Brunswick, NJ. All other chemicals used were of research grade. 
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3. Methods 
3.1. Phase Solubility Studies 
Phase solubility studies were performed according to the standard protocol46. Solubility 
measurements were carried out at constant temperature (25 ˚C) using different concentrations of 
aqueous solutions of CAP. A large excess of propofol (200 mg) was added to 3ml of water with 
accurately weighed amount of CAP and diluted to concentrations of 0.02, 0.04, 0.08, 0.1 and 
0.15 M in screw capped scintillation vials. The resulted solution was vortexed for 5 min and was 
shaken for 5 days using rotary LabquakeTM tube shaker (Labindustries, Inc. Berkeley, CA). 
Then, an aliquot of aqueous phase from each mixture was withdrawn, centrifuged for 15 min at 
13000 RPM and the supernatant was discarded and the remaining content was filtered through 
0.45 µm cellulose acetate membrane filter47. A portion of clear filtrate was diluted appropriately 
and analyzed using high performance liquid chromatography (HPLC).  
3.2. Preparation of propofol-captisol® complex 
Propofol:captisol® (P-CAP) inclusion complex was prepared by freeze-drying method. The 
aqueous solution of P-CAP complex was prepared by dissolving propofol (100 mg) in 10 ml of 
18% w/v solution of CAP in distilled water. The resulting mixture was vortexed for 15 min and 
sonicated for 20 min followed by setting aside at 25 ˚C for 48 h to attain equilibrium solubility. 
The clear solution was then subjected to freeze drying for 24 h to obtain white powder.  
3.3. UV-Spectrophotometric Studies 
Samples were prepared by dissolving freeze-dried complex and neat propofol (control) in 
distilled water. The samples were analyzed using UV spectrophotometer and any shift in the λmax 
or absorption intensity was recorded.  
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3.4. NMR spectroscopy 
Inclusion complex of P-CAP was characterized by high-resolution nuclear magnetic 
resonance spectra (1H NMR). Samples of propofol and P-CAP complex were prepared by 
dissolving, a portion of freeze-dried powder in deuterium oxide (D2O) and propofol in deuterated 
chloroform (CDCl3). Spectra’s were recorded on a Brucker Ultraspec 400 MHz/100 MHz 
spectrometer (Brucker Biospin Corporation, Woodlands, TX). Chemical shifts were reported in 
parts per million (δ) and 1H NMR signals were quoted as s (singlet), d (doublet), t (triplet), and m 
(multiplet).  
3.5.  In vitro transport studies 
3.5.1. Preparation of Porcine Epidermis 
Freshly excised porcine belly skin was obtained from the local abattoir. The obtained skin 
was washed carefully with saline followed by removal of subcutaneous fat and the pieces of the 
skin were wrapped in aluminum foil and heated to 60 °C for 2 min. Then the epidermis was 
gently peeled off the skin and stored at 4 °C until further use. 
3.5.2. General Experimental Setup 
A vertical Franz diffusion apparatus (Logan Instruments, Somerset, NJ) was used for all 
transport studies. The receiver compartment was filled with 5 mL of freshly prepared phosphate 
buffered saline (PBS) (pH 7.4) with 30% alcohol and donor compartment with 0.5 mL of 
permeant solution. The electrical resistance of epidermis was measured with the help of an 
electric circuit consisting of a waveform generator and digital multimeter (Agilent Technologies, 
Santa Clara, CA). Epidermis with a resistance ≥20 kΩcm2 was considered for permeation 
studies. One mL of sample from the receiver compartment was withdrawn at pre-determined 
time points and estimated for propofol using HPLC. 
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3.5.3. Transport studies across porcine epidermis 
In vitro passive permeation studies were carried out using the experimental setup described 
in the above section. P-CAP complex at 10 mg/mL concentration in the donor compartment was 
used for transport studies across the porcine epidermis, whereas propofol dissolved in 30% 
alcohol was used as control at same concentration. Permeation studies were carried out for a 
period of 8h and samples were analyzed for propofol using HPLC technique. The details of 
analytical method are discussed in section 3.7. 
For in vitro iontophoretic permeation of P-CAP complex, the experimental setup remained 
same as described in the above section. Additionally, constant current cathodal iontophoresis was 
performed using Phoresor® iontophoresis unit (Iomed, Salt Lake City, UT) at a current density of 
0.5 mA/cm2.  
3.6. Pharmacokinetic Studies 
Pharmacokinetic studies were carried out in Sprague–Dawley rats. The rats weighing ~250–
300 g were purchased from Harlan Laboratories (Indianapolis, Indiana) and maintaining 12 h 
light–dark cycle allowed to acclimate in an animal facility with unlimited access to food and 
water. The rats were divided into two groups. One of the groups was passive transdermal 
delivery (n = 4) and the second group was iontophoretic delivery of propofol from its CAP 
complex (n = 6). In both the groups, the time course of drug in the plasma was determined 
following transdermal administration of propofol from its complex. The animals were 
anesthetized using ketamine (80 mg/mg) and xylazine (10 mg/kg) via the intraperitoneal route 
during the period of study. Custom made patch system loaded with P-CAP complex (10 mg/mL) 
was applied to both the passive and iontophoresis groups. The patches were placed on the lateral 
surface of the skin. Alongside, another patch containing conducting gel (Sigma gel; Parker 
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Laboratories, Inc., Fairfield, New Jersey) was also placed on the rat. To perform iontophoresis, a 
cathodal electrode was connected to the patch containing P-CAP complex solution and the 
anodal electrode was connected to the patch containing conducting gel. Iontophoresis was 
performed by applying a constant current of 0.5 mA/cm2 across the electrodes by using Iomed 
Phoresor II dose controller (Iomed Inc.) for a period of 4 h. In the case of control, the setup was 
similar except that the current was not applied. Blood samples (200 μl) were withdrawn for a 
period of 6 h from the retro-orbital plexus and placed in heparinized tubes and centrifuged at 
8000 g for 3 min. The plasma proteins were precipitated with acetonitrile and the supernatant 
was analyzed for drug content by using validated HPLC method, which is described in detail 
under Section 3.7. 
3.7. Analytical Method 
The HPLC system (Waters Corp, Milford, MA) consisting of model 1525 isocratic 
chromatographic pump equipped with an auto-sampler (Waters 717 plus), a UV detector (Waters 
2487) and a reversed phase Symmetry® C18 (4.6 x 150 mm; 5 µm particles) column with a 
security guard cartridge, was used. Analysis of propofol samples were carried out at a 
wavelength of 254 nm, and the mobile phase consisted of a mixture of water and methanol 
(20:80 v/v) with an optimized flow rate of 1 mL/min. Standard solutions of propofol were 
prepared in methanol and calibration curve was plotted against area vs concentration48.  
4. Results 
4.1. Phase solubility studies 
The phase solubility studies revealed that different concentrations of aqueous solutions of 
CAP and propofol in solution were correlated linearly representing an AL type curve
4s. This data 
suggests that the stoichiometry of the complex is most likely to be 1:1. Since, the slope of this 
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plot is less than 1 (0.0074), the apparent stability constant was calculated using the equation Kc = 
Slope/S0 (1-slope) (where S0 is the solubility value of propofol in water) and was found to be 
1426.8 M-1 (Fig 6). 
 
 
Figure 6: Phase solubility studies of propofol and CAP. 
4.2. Characterization of inclusion complex 
Generally complexation with cyclodextrin leads to a change in the absorption spectrum of 
guest molecules due to inclusion of chromophore of the guest molecule in cyclodextrin50. In the 
present case, the UV absorption spectra indicated a small shift in the λmax of propofol from 254 to 
255.5, indicating complex formation between CAP and propofol. 
Further, NMR studies were performed to confirm the complex formation between 
propofol and CAP. NMR spectroscopy is one of the most widely used techniques to study CD 
inclusion complexes51. 1H NMR spectroscopic studies were carried out to investigate the 
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formation of complex between propofol and CAP. It is clear from the data in Table 1 that there is 
a significant down field shift with all the protons of propofol in the presence of CAP. Likewise, 
the chemical shifts in case of protons corresponding to CAP in the presence and absence of 
propofol further confirmed the formation of inclusion complex (Table 2)52.  
Propofol Proton 
Propofol 
Chemical Shift 
Values 
P-CAP complex 
Chemical Shift 
Values 
Difference in 
the Chemical 
Shift Values 
Peak 
Multiplicity 
H-3 6.5 7.07 0.57 Doublet 
H-4 6.4 6.88 0.48 Triplet 
H-5 2.5 3.24 0.74 Septet 
H-6 0.7 1.2 0.5 Doublet 
  
Table 3: 1H chemical shifts corresponding to propofol in the absence and presence of CAP. 
 
CAP proton 
CAP  
Chemical Shift 
Values 
P-CAP Complex 
Chemical Shift 
Values 
Difference in the 
Chemical Shift 
Values 
H-1 5.13 5.05 0.08 
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H-2 1.73 1.72 0.01 
H-3 3.60 3.55 0.05 
H-4 2.90 2.87 0.03 
H-5 3.89 3.77 0.12 
 
Table 4: 1H chemical shifts corresponding to CAP in the absence and presence of propofol. 
4.3. Transport studies across porcine epidermis 
4.3.1. Passive transport studies 
In vitro passive and iontophoretic transport of propofol from propofol alone and P-CAP 
complex was investigated across the porcine epidermis. The passive flux of propofol from P-
CAP complex was 17.04±2.41 µg/h/cm2, whereas passive flux of propofol from control set (only 
neat propofol was placed in the donor) was found to be 4.64±1.68 µg/h/cm2 (Fig 7). Indeed, this 
was intriguing data as the passive delivery of propofol was enhanced almost 4 fold by the 
complex as compared to neat propofol. This suggests the likelihood of CAP possessing the 
property of enhancing passive transdermal delivery of lipophilic drugs. In the past, several 
research groups have extensively studied the effect of different CDs as transdermal permeation 
enhancers. Recently, Badili and co-workers have reported that CAP enhanced the transport of 
calcipotriol across dialysis membrane barrier from an emulgel formulation. The enhancement in 
permeation of calcipotriol in presence of CAP was attributed to improved solubility and 
dissolution characteristics of the complex over the neat calcipotriol. However, the authors did not 
provide any information on permeation studies across biological membrane to demonstrate the 
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potential of CAP as transdermal permeation enhancer53. In another study, Vollmer and co-
workers have investigated the effect of 20% aqueous solutions of 2-hydroxypropoyl-β-CD 
(HPCD) and 2,6 - dimethyl-β-CD (DBCD) on the transdermal permeation of liarozole on rat 
model, in vivo. They found a 3-fold enhancement in absorption of drug when applied a solution 
of HPCD. Whereas, pretreatment with 20% w/v DBCD for 4h enhanced the permeation of 
liarozole by ~9 fold. The mechanism of drug penetration enhancement was investigated using 
differential scanning calorimeter (DSC) as a tool. The authors reported that DBCD was found to 
disrupt the SC barrier thus enhancing the skin permeability. On the other hand, HPCD was found 
to have no interaction with the stratum corneum and rather enhanced the partitioning of the drug 
into skin54. There are no reports on the use of CAP as a skin transport-enhancing agent so far. 
 
Figure 7: In vitro transport profile of propofol across porcine epidermis when the donor 
solution was placed with, neat propofol (Control) (▲), P-CAP complex (equivalent to 10 
mg/ml propofol) (■).  Transport of propofol by iontophoresis from P-CAP complex solution 
(♦). 
31 
 
4.3.2. Iontophoretic transport studies 
The passive flux of propofol from P-CAP complex was further enhanced by four fold 
(62.35±5.27 µg/h/cm2) due to application of cathodal iontophoresis. Cathodal iontophoresis was 
applied as the P-CAP complex was expected to possess a net negative charge. This data 
supported our hypothesis that complexation with CAP would render the lipophilic molecule 
amenable to iontophoresis. There was a significant change in the pH of the donor compartment 
during iontophoresis as we used aqueous solution of the complex instead of buffers to keep the 
solution devoid of any competing ions. Considering the low pKa value of sulfonic acid groups on 
the CAP, increase in the pH in donor compartment due to hydrolysis of water during 
iontophoresis is not likely to affect the iontophoretic transport significantly55. Although it is 
obvious to speculate that the predominant mechanism contributing to enhance delivery of 
propofol (from P-CAP) by iontophoresis would be electrorepulsion, the role of other potential 
mechanisms cannot be completely neglected. Mechanistic studies were performed to assess the 
potential role of other possible mechanisms in enhancing the transport of propofol across the 
epidermis passively as well as iontophoretically form the P-CAP solution, which is discussed in 
detail in the next chapter. 
4.4. Pharmacokinetic Study 
The plasma propofol level in control group (passive) was below detection at all-time points 
during the study. Iontophoresis of propofol alone (without CAP) was not possible due to the 
absence of any charge on the propofol molecule. The plasma concentration–time profile after 
transdermal iontophoretic delivery in the form of P-CAP was fitted to a non-compartmental 
model and the elimination half-life of the propofol was found to be 22.71 ± 5.77 min, which is in 
agreement with elimination for intravenous administration reported in the literature56 (Fig 8).  
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Figure 8: Plasma concentration of propofol after transdermal delivery of P-CAP from 
patch loaded with 10 mg/mL of P-CAP complex with iontophoresis (♦) and without 
iontophoresis (passive delivery) (■). 
Further, propofol kinetics in the brain following I.V infusion and transdermal 
iontophoresis was found to be comparable (Fig 9). 
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Figure 9: Pharmacokinetic studies of propofol in brain following I.V infusion (■) and 
transdermal iontophoresis (♦) of P-CAP complex. 
5. Conclusions 
Phase solubility, 1H NMR and UV-spectrophotometric studies confirmed Propofol and CAP 
complex formation. The results obtained from the in vitro permeation studies demonstrated the 
feasibility of iontophoresis of lipophilic drugs by the way of complexing with anionic 
cyclodextrin. Also, the results from pharmacokinetic study clearly demonstrate the ability of 
iontophoresis to deliver propofol via transdermal route after complexing with CAP, which could 
potentially overcome the disadvantages of marketed lipid formulation.  
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CHAPTER 4 
TRANSDERMAL IONTOPHORETIC DELIVERY OF IBUPROFEN 
1. Introduction 
Ibuprofen is an effective non-steroidal anti-inflammatory drug (NSAID) often used in the 
treatment of acute and chronic arthritic conditions57. Since, the oral delivery of ibuprofen is 
associated with severe gastric side effects; there is need for development of alternate routes of 
delivery. Transdermal delivery of ibuprofen from different formulations was studied by several 
research groups; however inherent transdermal permeability is low due to higher log P value58, 59. 
Therefore, the effect of complexation with anionic cyclodextrin (CAP) in enhancing the 
permeation of lipophilic drug, ibuprofen was studied.  
2. Materials 
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand 
Pharmaceuticals, La Jolla, CA). Ibuprofen was purchased from Sigma Aldrich (St. Louis, MO). 
Deuteriumoxide (99.5 mol% D) were purchased from Sigma-aldrich (St. Louis, MO, USA). All 
other chemicals used were of research grade.Methods 
2.1. Phase solubility studies  
Phase solubility studies were performed according to the procedure described in the previous 
chapter and the Ibuprofen - sulfobutyl ether-β-cyclodextrin (I-CAP) complex was prepared and 
characterized by solubility and NMR studies. 
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2.2. NMR spectroscopy 
The 1H-NMR was performed using a Bruker Avance 400 MHz spectrometer for protons in 
deuterium oxide as a solvent. The δ scale relative to tetramethylsilane was calibrated to the 
solvent value δ = 4.69 ppm for D2O.   
2.3. In vitro Permeation Studies 
The passive and iontophoretic permeation of ibuprofen from cyclodextrin complex solution was 
carried out using vertical Franz diffusion apparatus. I-CAP complex at 10 mg/mL concentration 
in the donor compartment was used for transport studies across the porcine epidermis, whereas 
ibuprofen dissolved in 50% alcohol was used as control at same concentration. Permeation 
studies were carried out for a period of 24 h and samples were analyzed for ibuprofen using 
HPLC technique. 
3. Results 
3.1. Phase Solubility Studies 
The phase solubility studies revealed that different concentrations of aqueous solutions of CAP 
with ibuprofen in solution were correlated linearly representing an AL type curve (Fig 10). 
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Figure 10: Phase-solubility profiles of Ibuprofen and CAP. 
3.2. NMR Studies 
The formation of the complexes between ibuprofen and CAP was studied using 1H-NMR 
spectroscopy. Proton NMR spectra were recorded from the solutions of CAP and I-CAP in D2O 
to simulate the complexation in aqueous condition. The chemical shifts in case of protons 
corresponding to CAP in the presence and absence of ibuprofen confirmed the formation of 
inclusion complex60. 
3.3. Permeation studies across porcine epidermis 
Passive delivery of I-CAP solution formulation resulted in flux of 1.98±0.71 µg/cm2/h, which is 
comparable with the flux achieved in case of alcoholic solution of ibuprofen used as control 
(1.93±0.24 µg/cm2/h) (Fig 11).  
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Figure 11: In vitro transport profile of ibuprofen across porcine epidermis when the donor 
solution was placed with, ibuprofen in 50% alcohol (Control) (♦), I-CAP complex 
(equivalent to 10 mg/ml ibuprofen) (■).  Transport of ibuprofen by iontophoresis from I-
CAP complex solution (▲). 
 
Further, iontophoresis of I-CAP complex solution resulted in a flux of 9.29±1.19 µg/cm2 h which 
is ~5 fold more compared to the passive permeation of I-CAP complex and control.  
4. Conclusions 
It was clear from the passive permeation studies that, the flux achieved from I-CAP complex was 
almost equal to the flux achieved in case of control (50% alcohol). Since, alcohol is well 
established as transdermal permeation enhancer, the flux achieved in case of passive delivery of 
I-CAP complex can be considered as enhanced permeation. Further, the results from 
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iontophoretic studies demonstrated the ability of CAP as permeation enhancer for lipophilic 
drugs like ibuprofen. 
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CHAPTER 5 
TRANSDERMAL DELIVERY OF TESTOSTERONE (FROM CAP COMPLEX) FROM 
A HYDROGEL FORMULATION 
1. Introduction 
Testosterone is the major circulating male androgen. Its deficiency is usually associated with 
adverse effects on body composition, bone density, sexual function and mood, and may also 
increase cardiovascular risk61. Gel formulations are already used clinically for the delivery of this 
hormone (e.g. Androgel®). However, these formulations have to be applied over large surface 
areas to achieve the target plasma levels which poses the risk of cross absorption who come in 
contact with the treated individual. Therefore there is need for improving the rate of delivery of 
testosterone from topical products to reduce the required area of application62.  
The first major objective of this project was to explore if testosterone delivery across the skin 
could be enhanced by iontophoresis, using CAP as complexing agent. The second objective was 
to investigate the feasibility of complexation of CAP with lipophilic drugs from hydrogel 
formulation (please note that the earlier investigations were performed in aqueous solution).  
2. Materials 
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand 
Pharmaceuticals, La Jolla, CA). Hydroxypropyl-β-cyclodextrin was obtained from Roquette 
America, Inc (Geneva, IL). Testosterone was purchased from Sigma Aldrich (St. Louis, MO). 
Ag wire was from Alfa Aesar, Ward Hill, MA. Dialysis membrane molecular weight cut off 
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(MWCO) 1000Da was from Spectrum Chemicals, New Brunswick, NJ. All other chemicals used 
were of research grade. 
3. Methods 
3.1. Phase solubility studies  
Phase solubility studies were performed according to the standard protocol. Solubility 
measurements were carried out at constant temperature (25 ˚C) using different concentrations of 
aqueous solution of CAP. A large excess of testosterone (200 mg) was added to 3ml of water 
with accurately weighed amount of CAP and diluted to concentrations from 0.002 to 0.02 M in 
screw capped scintillation vials. The resulted solution was vortexed for 5 min and was shaken for 
5 days using rotary LabquakeTM tube shaker (Labindustries, Inc. Berkeley, CA). Then, an aliquot 
of aqueous phase from each mixture was withdrawn, centrifuged for 15min at 13000 RPM and 
the supernatant was collected and filtered through 0.45 µm cellulose acetate membrane filter. A 
portion of clear filtrate was diluted appropriately and analyzed using high performance liquid 
chromatography (HPLC).  
3.2. Preparation of solid complex mixture 
Captisol-enabledTM testosterone (T-CAP) complex was prepared by freeze-drying method. 
The aqueous solutions of complex were prepared by dissolving 100mg of drug in 10 mL of 10% 
CAP in distilled water for testosterone, respectively. The resulting mixture was vortexed for 
15min and sonicated for 20 min followed by setting aside at 25 ˚C for 48 h to attain equilibrium 
solubility. The clear solution (10 mL) was then subjected to freeze drying for 24 h to obtain 
white powder.  
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3.3. Transport studies across porcine epidermis from aqueous and hydro-
alcoholic solution 
The vertical Franz diffusion apparatus (Logan Instruments, Somerset, NJ) was used for all 
transport studies. The receiver compartment was filled with 5 mL of freshly prepared phosphate 
buffered saline (PBS) (pH 7.4) with 30% alcohol and donor compartment with 0.5 mL of 
permeant solution. In vitro passive permeation studies were carried out using aqueous solution 
containing the drug-Captisol complex (dissolved in water) equivalent to 10 mg/mL of drug in the 
donor compartment. As the pure drug is not soluble in water, a solution of pure drug dissolved in 
50% alcohol was used as control at same concentration.  
For in vitro iontophoretic permeation of complex, constant current cathodal iontophoresis 
was applied using Phoresor® iontophoresis unit (Iomed, Salt Lake City, UT) at a current density 
of 0.5 mA/cm2. Permeation studies were carried out from solution formulation after dissolving 
the complex in water at same concentration as passive delivery (10 mg/mL) for a period of 24 h 
and samples were analyzed using HPLC technique63. 
3.4. Preparation and release studies of testosterone from Hydroxypropyl Methyl 
Cellulose (HPMC) Gels  
HPMC gel was prepared by Hot/Cold technique at 3.5% w/v concentration. T-CAP complex 
was incorporated at 10 mg/mL concentration in the gel. Further, the release of testosterone from 
T-CAP gel formulation was investigated across 1000 Da molecular weight cutoff SpectraPor® 
dialysis membrane using vertical Franz diffusion apparatus.  
3.5. Transport studies across porcine epidermis from HPMC gel formulation 
Transport of testosterone from the HPMC gel formulation across porcine epidermis was 
studied by both passive and iontophoretic mediated delivery for a period of 24 h and sample 
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from the receiver compartment was withdrawn at pre-determined time points and estimated for 
testosterone using HPLC63. 
4. Results 
4.1. Phase solubility studies 
The phase solubility studies revealed that different concentrations of aqueous solutions of 
HPCD and CAP with testosterone in solution were correlated linearly representing an AL type 
curve (Fig 12). From the phase solubility curves, the stability constant and complexation 
efficiency of the two complex solutions was calculated and shown in Table 5. 
        
Figure 12: Phase-solubility profiles of Testosterone in HP-β-CD and CAP. 
 
 
HP-β-CD SBE-β-CD 
S0 5.18E-05 5.185E-05 
m (Slope) 0.544 0.354 
1-m 0.456 0.646 
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S0 (1-m) 0.000 0.000 
m/S0(1-m) 23008.9 10569.0 
K 1:1 23008.9 10569.0 
CE 1.193 0.548 
 
Table 5: Summary of Cyclodextrin Stability Constants and Complexation Efficiency. 
4.2. NMR Studies 
The formation of the complexes between testosterone and CAP was studied using 1H-NMR 
spectroscopy. Proton NMR spectra were recorded from the solutions of CAP and T-CAP in D2O 
to simulate the complexation in aqueous condition. The chemical shifts in case of protons 
corresponding to CAP in the presence and absence of testosterone confirmed the formation of 
inclusion complex64. 
4.3. Passive permeation studies  
Passive delivery of T-CAP and T-HPC solution formulations resulted in 4.46±1.21 µg/cm2 
and 7.74±3.71 µg/cm2 testosterone transported at the end of 24 h, which is comparable with the 
cumulative amount of drug permeated in case of alcoholic solution of testosterone used as 
control (5.11±0.68 µg/cm2) (Fig 13).  
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Figure 13: Passive permeation profiles of T-CAP (■), T-HPC (♦) and testosterone dissolved 
in 67% alcohol (▲) from solution formulations. 
4.4. Release studies of testosterone from HPMC gels 
Release of testosterone from HPMC gel formulations with T-CAP and T-HPC complexes 
was studied using 1000 Da molecular weight cut off membranes. The amount of drug released 
was ~48% and ~44% at the end of 24 h with T-CAP and T-HPC complexes, respectively (Fig 
14). The molecular weight of the T-CAP complex (2.3 kDa) and T-HPC (1.7 KDa) is way higher 
than the MWCO of membrane (1 kDa), suggesting that the amount of drug in the receiver 
compartment was predominantly due to the ability of CDs to enhance the thermodynamic 
activity of drug in the donor compartment. 
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Figure 14: Release profiles of testosterone from T-CAP (■) and T-HPC (♦) incorporated in 
HPMC gel. 
4.5. Permeation studies across porcine epidermis from HPMC gel 
The amount of testosterone permeated from these gel formulations across the porcine 
epidermis in 24 h was found to be 2.45±0.92 µg/cm2 and 2.96±0.61 µg/cm2 with T-CAP and T-
HPC, respectively (Fig 15). Decrease in the cumulative amount permeated across the porcine 
epidermis compared to solution formulation can be accountable to increase in the viscosity due 
to HPMC. 
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Figure 15: Passive permeation profiles of T-CAP (■), T-HPC (♦) from gel formulations. 
4.6. Iontophoretic transport of T-CAP from solution and gel formulations 
The cumulative amount of testosterone permeated after cathodal iontophoresis of T-CAP 
complex solution was 124.85±8.01 µg/cm2, which is ~30-fold greater than passive delivery. 
Further, iontophoresis using the hydrogel containing T-CAP resulted in permeation of 
48.12±6.12 µg/cm2 (Fig 16). There was a significant change in the pH of the donor compartment 
during iontophoresis was observed as the complex dissolved in water was used for iontophoretic 
permeation studies instead of buffers to keep the solution devoid of any competing ions. 
Considering the low pKa value of sulfonic acid groups on the CAP, an increase in the pH in 
donor compartment due to hydrolysis of water during iontophoresis is not likely to affect the 
iontophoretic transport significantly65. To minimize the effect of pH changes on the permeation 
of drug across the skin, the drug solution in the donor was replaced intermittently with freshly 
prepared drug-CAP complex solution.  
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Figure 16: Passive permeation profiles of T-CAP from solution (●) and HPMC gel (▲) 
formulations and Iontophoretic permeation profiles of T-CAP from solution (■) and 
HPMC gel (♦) formulations. 
5. Conclusions 
The results from these studies demonstrate that the cyclodextrin derivatives CAP and 
HPβCD could be used to deliver lipophilic molecules like testosterone from semisolid 
preparations. The use of these cyclodextrin derivatives could potentially eliminate the use of 
alcohol in the formulation. Further, iontophoresis of T-CAP complex solution resulted in a flux, 
which is ~25 fold more compared to the flux achieved in case of control (Testosterone dissolved 
in 67% alcohol) and ~48 fold more when compared to passive delivery of T-CAP complex. 
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CHAPTER 6 
MECHANISMS CONTRIBUTING TO TRANSDERMAL TRANSPORT OF 
LIPOPHILIC DRUGS COMPLEXED WITH CAPTISOL 
1. Introduction  
Propofol:captisol® (P-CAP) complex was used to investigate the potential mechanisms 
responsible for enhancement of transdermal delivery of drug when complexed with CAP. From 
passive permeation standpoint, stratum corneum has been known to be permeable to small (<500 
Da) and moderately lipophilic molecules only66. The P-CAP complex is about 2 kDa, which is 
way above the known size-exclusion limit of stratum corneum. However, there was a significant 
enhancement in the delivery of propofol from P-CAP complex. Initially, it was not clear if the 
whole intact complex would be able to transport across the epidermis or its propagation is 
limited only up to the donor-epidermal interface. The other question that arises was if at all the 
transport of intact complex across the epidermis is practical, then would application of 
iontophoresis drive more intact complex due to electrorepulsion? This is because; the 
electrorepulsion is known to diminish as the size of the molecule increases67. Electrorepulsion is 
determined by charge to mass ratio, rather than the charge alone. To address these questions, 
transport studies were performed to investigate the permeation of neat CAP across the porcine 
epidermis. Also, the effect of CAP on the structural integrity of stratum corneum was studied 
using FTIR and skin electrical resistance studies. Further, to demonstrate the effect of CAP in 
enhancing the thermodynamic activity in the donor compartment, transport studies were 
performed across a non-biological membrane.  
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2. Materials 
Sulphobutyl ether-β-cyclodextrin (Captisol®) was obtained as gift sample from Ligand 
Pharmaceuticals, La Jolla, CA). Ibuprofen, testosterone and propofol were purchased from 
Sigma Aldrich (St. Louis, MO). Ag wire was from Alfa Aesar, Ward Hill, MA. Dialysis 
membrane molecular weight cut off (MWCO) 1000Da was from Spectrum Chemicals, New 
Brunswick, NJ. All other chemicals used were of research grade. 
3. Methods 
3.1. General in vitro experimental setup  
A vertical Franz diffusion apparatus (Logan Instruments, Somerset, NJ) was used for all 
resistance, transport and mechanistic studies. A piece of epidermis was placed between the donor 
and receiver compartments with temperature maintained at 37±1 ˚C using water circulator. 
Effective surface area for transport studies was kept constant at 0.64 cm2. The receiver 
compartment was filled with 5 mL of freshly prepared phosphate buffered saline (PBS) (pH 7.4) 
with 30% methanol and donor compartment with 0.5 mL of permeant solution. The electrical 
resistance of epidermis was measured with the help of an electric circuit consisting of a 
waveform generator and digital multimeter (Agilent Technologies, Santa Clara, CA). Epidermis 
with a resistance ≥20 kΩcm2 was considered for permeation studies. One mL of sample from the 
receiver compartment was withdrawn at pre-determined time points and estimated for propofol 
using HPLC. 
3.2. Trans-epidermal transport of Rhodamine labeled Captisol®  
In vitro iontophoretic and passive transport of Rhodamine labeled CAP (R-CAP) was carried 
out across the porcine epidermis. 0.5 mL of 18% w/v of R-CAP was placed in the donor 
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compartment. The experimental setup remains same as described in previous section. Samples 
from the receiver compartment was collected and for the amount of R-CAP was measured using 
fluorescent spectroscopy at excitation wavelength of 515 nm and emission wavelength of 556 
nm. The R-CAP concentration was calculated from the standard calibration curve made by using 
different standard concentrations of R-CAP68. 
3.3. Trans-epidermal electrical resistance studies  
Freshly excised porcine epidermis having a resistance of ≥20 kΩcm2 was chosen for carrying 
out the studies. The electrical resistance of skin was measured with the help of an electric circuit 
consisting of a waveform generator and digital multimeter having a load resistor RL (100 kΩ) in 
series with the skin. Ag/AgCl electrode wires of 0.5 mm diameter (Alfa Aesar, Ward Hill, MA) 
made in the form of concentric rings were placed 2 mm away from the porcine epidermis in both 
the donor and the receiver compartments to measure the electrical resistance. The voltage drop 
across the whole circuit (V0) and across the skin (Vs) was measured and skin resistance was 
determined by applying a voltage of 100 mV at 10 Hz in the circuit. The drop and recovery of 
electrical resistance in presence of CAP in the donor compartment during and after iontophoresis 
were recorded. PBS in the donor compartment was used as test solution in control experiments.  
3.4. FTIR spectroscopy 
Porcine epidermis was separated from the dermis of full thickness skin by heat stripping 
technique. Isolated epidermis was then floated over 0.25% w/v trypsin solution overnight at 
room temperature to digest the epidermis69. The residual stratum corneum (SC) was then washed 
with phosphate buffer and dried at room temperature for 48h. The SC was then cut into square 
pieces of 2 X 2 cm. Each piece was placed in the 10% w/v and 20% w/v of CAP solution in 
water, whereas SC placed in the buffer was used as control. SC pieces were incubated in 
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solutions for a period of 24 h and then washed thoroughly with water to remove any excess CAP 
on surface.  The SC pieces were then dried at room temperature for 48 h at the end of which 
interferograms were recorded. Mid-infrared spectra were collected on an FTIR (Agilent 
Technologies Cary 660). The bench was equipped with a sampling accessory (MIRacle ATR, 
Pike Technologies), which was fitted with a single bounce diamond coated ZnSe internal 
reflection element. The spectra were collected from 4000-650cm-1. The spectra were analyzed 
using the Agilent’s software suite (Resolutions Pro Version 5.2.0). Each sample was studied in 
triplicate to assess its effect on the SC. 
3.5. Transport studies across dialysis membrane  
Passive and iontophoretic transport studies of propofol and P-CAP complex solutions at 10 
mg/mL concentration was carried out using dialysis membrane (1000 Da MWCO). The 
experimental setup remained similar to general experimental setup, except that the porcine 
epidermis was replaced with dialysis membrane. Iontophoresis of P-CAP complex was carried 
out at a current density of 0.5m A/cm2. 
3.6. Effect of pretreatment with chemical permeation enhancers 
Different CPEs include, 5% w/v menthol, propylene glycol (PG), oleic acid (OA), and 
ethanol was used to investigate the effect on iontophoretic delivery of propofol from P-CAP 
complex with the experimental setup remain same as described in section 2.1. Initially, porcine 
epidermis was treated with CPEs for a period of 3 h and followed by washing thoroughly with 
distilled water. Then the donor compartment was filled with 0.5 mL of P-CAP solution and 
iontophoresis was performed at a current density of 0.5 mA/cm2. 
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3.7. MTT assay 
Cell viability of dermal fibroblast derived from humans (CCD-1093Sk) was studied using the 
CAP solutions. Fibroblast cultures were stored and handled according to the standard protocol 
from ATCC. To study the effect of the CAP formulation on cell viability, cell cultures were 
exposed to different concentrations ranging from 0.5 to 2 % w/v for a period of 24 h. Each test 
formulation was studied in eight trials. MTT (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) cell proliferation assay was 
performed according to the protocol supplied by Promega. The optical absorbance data from the 
samples were then used to calculate the percentage cell viability. 
4. Results and Discussion 
4.1. Transport of Rhodamine labeled Captisol® across the porcine epidermis 
Some earlier works have already reported that skin permeable to different cyclodextrins to 
different extents in the molecular weight range of ~1kDa72-75. Gerloczy and co-workers reported 
that [14C] Dimethyl-β-Cyclodextrin was poorly absorbed (0.3-0.4%) when the ointment at 40 - 
49 mg/mL concentration was applied onto the skin of rats under occlusive conditions75. In 
another study, Tanaka and co-workers have reported that, 0.02% of HPCD was absorbed into 
hairless mouse skin under occlusive conditions at 20 mg/mL concentration in the donor 
compartment74. There is no data available regarding the passive and iontophoretic transdermal 
transport of CAP. Due to lack of sensitive methods of measurement of cyclodextrins, rhodamine 
labeled CAP (R-CAP) was used to investigate the permeability of CAP across the epidermis. The 
in vitro passive and iontophoretic permeation of R-CAP was studied to approximate the amount 
of propofol permeated in the form of intact complex. The amount of R-CAP permeated passively 
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was 0.16% (150.24±48.31 µg/cm2 in 8 h). Although relatively small amount, the fact that CAP 
permeated across the epidermis itself was interesting. This data suggests that despite the huge 
molecular size, the possibility of transport of intact P-CAP complex cannot be completely ruled 
out. Iontophoresis enhanced the transport of R-CAP to ~0.87% (804.43 ± 94.12 µg/cm2 in 8 h), a 
fivefold enhancement suggesting significant elelctrophoretic driving of the molecule. The 
efficiency of electrophoresis of R-CAP across the epidermis is likely because of the seven 
negative charges present on the molecule, which makes up for its huge molecular size with a 
transport number 0.003. The transport number of unit charge carrying smaller molecules which 
were successfully delivered transdermally by iontophoresis, such as diclofenac sodium is about 
0.00376, 77. This explains how R-CAP could appreciate the electrorepulsion mediated transport 
across the epidermis despite its relatively larger molecular size.  
To approximate the extent of transport of intact complex across the epidermis, one needs to 
look at the cumulative amount of propofol transported versus the total cyclodextrin transported 
across the epidermis. The cumulative amount of the propofol transported across the porcine 
epidermis from the P-CAP complex at the end of 8h was ~0.6 X 10-3 mmol and ~0.24 X 10-2 
mmol by passive and iontophoresis, respectively. If all of propofol had transported in the form of 
intact complex, the amount of CAP transported should be equivalent to the amount of propofol. 
However, in reality, the cumulative amount of propofol permeated was found to be more when 
compared to the cumulative amount of CAP permeated at the end of 8h (~ 0.69 X 10-4 mmol 
passively and ~0.37 X 10-3 mmol by iontophoresis). This data suggests that the transport of 
propofol cannot be absolutely in the intact P-CAP complex form. There appears to be 
contribution by other mechanisms as well.   
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4.2. Resistance studies of porcine epidermis 
To investigate the effect of CAP on the stratum corneum barrier, electrical resistance drop 
and recovery studies were carried in the presence of CAP at 18% concentration (concentration at 
which CAP is complexed with propofol for transport studies across the porcine epidermis). For 
control studies, electrical resistance of the epidermis was studied in the presence of freshly 
prepared PBS. Yamamoto and Yamamoto have demonstrated that the skin’s electrical resistance 
resides primarily in the SC78. Skin resistance decreased as layers of the SC were removed by tape 
stripping. They also reported that the passage of ions into and across the skin was increased, if 
the barrier function of SC is reduced in some way. Rachakonda and co-workers have studied 
extensively on skin electrical resistance after treating with chemical permeation enhancers. From 
the results, they found that electrical resistance measurement could be used to determine the 
effect of CPEs on the barrier property of skin79. 
In case of iontophoresis, the major route of ionic transport has been found to be appendageal 
pores including sweat ducts and hair follicles80. Apart from appendageal pathway, there are 
reports on formation of artificial shunts as a result of temporary disruption of organized structure 
of SC upon application of iontophoresis81. Caullander also reported the pore formation is 
dependent on the current potential applied and this can attribute to the flip-flop movements in 
polypeptide helices82.  
In the present study, the effect of CAP on the recovery of skin barrier perturbed due to 
iontophoresis treatment was investigated. The drop and recovery in the porcine epidermal 
resistance following iontophoresis at a current density of 0.5 mA/cm2 was studied with PBS and 
CAP solutions in the donor compartment. Drop in the electrical resistance was recorded using 
digital multimeter and waveform generator for a period of 1 h at every 5min interval. 
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Iontophoresis was stopped after 1 h and the recovery in the electrical resistance of the epidermis 
was recorded while retaining the donor solution. From the graph (Fig 17) plotted between 
relative resistance vs time, it clearly shows the delay in the recovery process in case of donor 
with CAP, whereas with PBS, there was a recovery up to ~90% within 2 h. The prolonged 
contact between CAP and epidermis did not lead to any significant drop/change in the electrical 
resistance compared to PBS in the absence iontophoresis (which served as control in this set of 
experiments). 
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Figure 17: The epidermal resistance as an indicator of permeability status of the porcine 
epidermis 
Sen and co-workers have studied the effect of anionic phospholipids on transdermal 
permeation after electroporation. They found that, only anionic lipids are expected to disrupt the 
tightly packed SC lipid lamellae and prolong the opening of the pathways83. In another study, 
Stewart and co-workers found that anionic lipids prefer loosely packed multi lamellae and are 
prone to develop and retain vesicular form upon physical perturbation, such as electric pulses, 
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thereby prolong the recovery84. CAP being a multi-anionic substance, it is likely to prolong the 
permeability status of the epidermis perturbed due to iontophoresis by a mechanism somewhat 
analogous to the anionic lipids reported earlier. It is intriguing to observe that the barrier 
recovered by 70% within two hours after replacing the donor compartment with PBS.  
4.3. FTIR spectroscopy of SC 
There was no significant shift in the peaks in the lipid region (2920 and 2850 cm−1) or in the 
amide regions (1650 and 1550 cm−1) as clearly seen in the representative spectra shown in Fig. 
18, even after exposure to 20% w/v CAP solution for a period of 24 h. This data supplements the 
hypothesis that the CAP used in this project has negligible or no effect on the skin structure69. 
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Figure 18: Representative FT-IR spectra of stratum corneum (Control and 20% CAP 
treated) and CAP. 
4.4. Transport studies across dialysis membrane 
Generally, CDs are known to act as carriers for the drug molecules and increases the 
availability of drugs at the membrane-reservoir interface. This in turn increases the concentration 
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gradient of drug across the membrane, resulting in enhanced driving force for permeation85, 86. 
To investigate if this is one of the potential mechanisms of permeation enhancement in case of 
propofol, the permeation studies were performed across a non-biological membrane (to avoid 
any interference due to biological factors), dialysis membrane of 1000 Da cut off molecular size. 
The permeation flux resulted from the passive transport studies of propofol and P-CAP was 
found to be 31.88±11.61 µg/cm2/h and 59.75±8.74 µg/cm2/h, respectively (Fig 19). The 
molecular weight of the complex (2.3 kDa) is way higher than the MWCO of membrane (1 kDa), 
suggesting that the enhanced transport (~2 fold) in passive permeation across the dialysis 
membrane was predominantly due to the ability of CAP to enhance the thermodynamic activity 
of drug in the donor compartment as observed in case of other CDs73, 86, 88.  
 
Figure 19: Passive permeation studies across dialysis membrane (1 kDa). Donor 
compartment was placed with propofol (▲), P-CAP complex (equivalent to 10 mg/ml 
propofol) (■) and iontophoretic transport of propofol from P-CAP complex (♦). 
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Electrophoresis and electro-osmosis are the two major mechanisms involved in driving of 
ions upon application of current across the membranes89. Since the isoelectric point of skin is 
between 4 – 4.5 and is negatively charged under physiological conditions; electro-osmosis 
occurs only in anode to cathode direction, whereas in case of cathodal iontophoresis 
electrorepulsion is the only mechanism driving the drug predominantly. Cathodal iontophoresis 
of P-CAP complex at the current density of 0.5 mA/cm2 lead to a transport flux of 134.83 ± 9.15 
µg/cm2/h of propofol (Fig 3), which is ~4.5 fold higher than passive permeation of propofol 
when neat propofol was placed in the donor and ~2.2 fold higher when compared to passive 
permeation from P-CAP complex. Again, as the transport of intact complex is not possible across 
the membrane used in this study, it is likely that the applied electric current drove the charged 
complex only up to the membrane surface. This essentially would enhance the transport of drug 
across the membrane.  
From the studies performed so far, it was evident that the passive permeation of drug was 
enhanced due to the mechanisms such as permeation of intact complex as well as due to the 
property of CAP to enhance the availability of drug at the membrane surface. In case of 
iontophoresis, the enhanced trans-epidermal drug transport was due to electrophoresis of intact 
complex leading to enhanced transport of intact complex as well as profoundly increased 
availability of drug at the membrane surface. However, the results discussed so far, did not 
reveal any information regarding the potential effects of CAP on the stratum corneum barrier. 
Therefore, further sets of studies were performed to investigate the effect of CAP on the stratum 
corneum barrier upon iontophoresis in the presence of CAP in donor compartment. 
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4.5. Effect of pre-treatment with chemical permeation enhancers  
The effect of pretreatment with CPEs on the iontophoretic transport of propofol from CAP 
complex was investigated to assess if the combination approach could be utilized to achieve 
higher doses of drugs if required. CPEs are known to decrease the skin’s barrier integrity of 
stratum corneum. However, due to the heterogeneity of skin structure, there exists number of 
different mechanisms by which these CPEs shows their action90. Kalia and Guy have studied the 
effect of pre-treatment with CPEs on iontophoresis across human skin using skin resistance as a 
tool91.  From the studies they reported that, pre-treating with CPEs reduced the skin resistance 
and further decrease in the skin resistance was observed upon iontophoresis at current density of 
0.2 mA/cm2.  
 
Figure 20: In vitro iontophoretic transport of propofol from P-CAP complex after 
pretreatment with different chemical permeation enhancers for 3h. Transport profile of 
propofol after pre-treating with 100% v/v Ethanol (X), 100% v/v Propylene Glycol (■), 5% 
w/v Menthol in 50% v/v Ethanol (●), 100% v/v Oleic Acid (♦) and PBS (control) (▲). 
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In the present study, the flux resulted from the in vitro iontophoretic transport of P-CAP 
complex after pre-treating with 100% v/v PG and 100 % v/v OA was found to be 47.96±4.54 
µg/cm2/h and 20.74±0.48 µg/cm2/h, which was less compared to control (62.35±5.27 µg/cm2/h). 
PG was chosen as enhancer, since it was reported to enhance the permeability of propofol across 
rat skin90. Despite the enhanced permeability of propofol when PG was used in the formulation, 
pre-treatment did not enhance the iontophoretic transport of propofol from P-CAP complex. It 
has been reported that, oleic acid facilitates transport through intercellular lipid domains by 
forming OA pool in the stratum corneum91. The iontophoretic transport of hydrophilic P-CAP 
complex might have reduced the flux when epidermis was pretreated with oleic acid. Menthol 
was another permeation enhancer evaluated in the study. Pre-treatment with 5% w/v of menthol 
in 50% w/w alcohol did not enhanced the flux (56.89±2.41 µg/cm2/h) when compared to control. 
This data also show that ethanol at 50% v/v lacks the ability to enhance the transport of propofol 
from P-CAP complex. Whereas, Pre-treatment with 100% v/v ethanol was found to enhance the 
flux by ~two fold (116.52±10.47 µg/cm2/h) (Fig 20). Ethanol mainly acts as permeation 
enhancer by increasing the partitioning in to stratum corneum92. Overall this study showed that 
the iontophoretic transport of propofol from P-CAP complex could be further enhanced when 
appropriate enhancer is used.  
4.6. MTT assay 
The MTT assay is a tool to assess the safety of captisol for dermal use. The previous studies 
have shown that CAP appears to penetrate the skin in significant amounts69.  Thus, cell viability 
studies on fibroblast (derived from humans) were performed at different concentrations of CAP 
solutions. The cell viability of non-treated cells was considered as 100%. More than 80% of cells 
were viable at 1.5% w/v concentration of CAP (Fig 21), with further increase in concentration to 
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2% w/v the % cell viability decreased to 76%, which is likely due to increased osmotic pressure 
in the medium (2% captisol in culture media has an osmotic pressure of 426 mOsmo/L).  
 
 
Figure 21: MTT assay of CAP at different concentrations. 
5. Conclusions 
Mechanistic studies reveled the fact that CAP can permeate the epidermis and its transport 
could be enhanced significantly by iontophoresis. The results from the in vitro permeation 
studies showed that the passive permeation of propofol could be enhanced by complexing with 
CAP. The predominant mechanisms responsible to enhanced drug permeation are transport of 
intact complex and increased localization of drug at the surface of the membrane. The 
mechanisms contributing to enhanced delivery of propofol from P-CAP complex by 
iontophoresis additionally includes electrorepulsive transport in the form of intact complex, 
profoundly increased localization of drug at the membrane surface and prolonged recovery phase 
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of skin barrier compromised due to iontophoresis. Further, the results from the MTT assay 
indicate the biocompatibility of CAP. 
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